In fact, first-dose bradycardia is a recognized pharmacodynamic effect of S1P modulators, and cases of transient sinus bradycardia or atrioventricular block have been documented with Etrasimod (Vermeire et al., 2025). The gene discussed is MBTPS1; the disease is atrioventricular block.